{"id":"W4286294471","doi":"10.1200/jco.2022.40.16_suppl.3031","title":"BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Translational Research in Oncology; Alberta Health Services; McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"FOLFOX; Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Interim analysis; Pharmacodynamics; Gastroenterology; Regimen; Pharmacokinetics; Pharmacology; Colorectal cancer; Oxaliplatin; Cancer; Adverse effect; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001320402,0.001425878,0.001365204,0.0005811584,0.0003532786,0.000964993,0.001082432,0.001394513,0.003911296],"category_scores_gemma":[0.0006337708,0.0005956427,0.0009818999,0.0005429995,0.0007596478,0.0007364745,0.0004053461,0.003770562,0.001028987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001108483,"about_ca_system_score_gemma":0.001815227,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001103018,"about_ca_topic_score_gemma":0.003159204,"domain_scores_codex":[0.9996315,0.0001680315,0.00001942614,0.00005515169,0.00005042075,0.00007543526],"domain_scores_gemma":[0.9994296,0.00007648632,0.0001283863,0.00004950272,0.00003897485,0.0002769587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3827017,0.2457141,0.006879738,0.001233058,0.001283236,0.0004995611,0.0005393081,0.006151242,0.183477,0.0007004832,0.01114107,0.1596796],"study_design_scores_gemma":[0.3080491,0.657806,0.01132219,0.00005174327,0.0003170642,0.000539718,0.00007577453,0.002540037,0.01371157,0.0002481789,0.005276468,0.00006223242],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898456,0.001771489,0.0008056655,0.0006351692,0.00007960256,0.002758638,0.001467565,0.0002027689,0.002433376],"genre_scores_gemma":[0.9798125,0.00227912,0.003785151,0.001329082,0.00009886806,0.003069176,0.004949916,0.00006872651,0.004607488],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003911296,"threshold_uncertainty_score":0.01308453,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04238617727844382,"score_gpt":0.3963305953709731,"score_spread":0.3539444180925293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}